Pipeline Therapeutics Inc. develops and commercializes small molecules for neuroregeneration, including synaptogenesis, remyelination, and axonal repair. The company’s lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor (GSI) to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy. The company also has a portfolio of earlier stage programs, including PIPE-307, focused on remyelination and axonal repair to address a range of neurological disorders, including multiple sclerosis. The company was founded in 2017 and is based in San Diego, California.
Botkin.AI is a software platform specializing in medical image processing and analysis through artificial intelligence. Founded in 2015 and based in Moscow, the company focuses on enhancing the capabilities of radiologists by providing advanced tools for analyzing radiograms and assessing the risk of tumors. Utilizing deep machine learning, Botkin.AI's technology enables healthcare providers to diagnose oncological diseases, such as lung cancer, with high accuracy and at early stages. By streamlining the processing of clinical data, the platform improves diagnostic efficiency while maintaining the quality of medical conclusions, ultimately supporting better patient outcomes.
Pipeline Therapeutics Inc. develops and commercializes small molecules for neuroregeneration, including synaptogenesis, remyelination, and axonal repair. The company’s lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor (GSI) to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy. The company also has a portfolio of earlier stage programs, including PIPE-307, focused on remyelination and axonal repair to address a range of neurological disorders, including multiple sclerosis. The company was founded in 2017 and is based in San Diego, California.
Botkin.AI is a software platform specializing in medical image processing and analysis through artificial intelligence. Founded in 2015 and based in Moscow, the company focuses on enhancing the capabilities of radiologists by providing advanced tools for analyzing radiograms and assessing the risk of tumors. Utilizing deep machine learning, Botkin.AI's technology enables healthcare providers to diagnose oncological diseases, such as lung cancer, with high accuracy and at early stages. By streamlining the processing of clinical data, the platform improves diagnostic efficiency while maintaining the quality of medical conclusions, ultimately supporting better patient outcomes.
Immusoft Corporation is a biotechnology company based in Seattle, Washington, focused on developing autologous cell therapies for various human diseases through its proprietary Immune System Programming (ISP) technology. Founded in 2009, the company modifies a patient's immune cells, specifically B cells, to create miniature drug factories that produce gene-encoded medicines, or biologics. By reprogramming these cells, Immusoft's technology enables the in vivo delivery of therapeutics that can replace missing or defective enzymes and proteins. The core ISP technology was initially developed at the California Institute of Technology and is exclusively licensed to Immusoft. This innovative approach aims to improve treatments for rare and infectious diseases by harnessing the body's own immune system.
Bonti, Inc. is a biotechnology company focused on developing neurotoxin products for both aesthetic and therapeutic uses. The company specializes in botulinum neurotoxin serotype E, with its primary products being EB-001A for aesthetic applications and EB-001T for therapeutic purposes. Originally founded as Endurance Biotech in 2015, the company rebranded to Bonti, Inc. in August of the same year. Based in Newport Beach, California, Bonti operates as a subsidiary of Allergan plc as of October 2018. The founding team includes Fauad Hasan, Mike Jarpe, Susan Abushakra, and Wajdie Ahmad.
RetroSense Therapeutics is a biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved drugs to improve or restore vision in patients with these retinal degenerative conditions. The company's approach to using optogenetics in vision restoration is based on pioneering, proprietary research conducted at Wayne State University and Massachusetts General Hospital. Founded in 2009, RetroSense Therapeutics is headquartered in Ann Arbor, Michigan.
Image Analysis Limited is a London-based company that specializes in medical imaging services and analytical software on a global scale. Founded in 2007, it provides support for clinical and pre-clinical studies, focusing on therapeutic effects in inflammatory arthritis and cancers. The company offers image analytics and biomarkers, as well as expert opinions and educational resources on the visualization and analysis of DCE-MRI and MRI images. Its services extend to early-phase trials and research and development studies. A key product, Dynamika, is an image analytics platform designed to process and evaluate images from patients with inflammatory and autoimmune conditions, including rheumatoid arthritis and various cancers. By integrating advanced technologies such as artificial intelligence and machine learning, Image Analysis Limited aims to enhance the efficiency and effectiveness of drug development processes.